Amylyx Pharmaceuticals (NASDAQ:AMLX) Sees Large Volume Increase After Analyst Upgrade

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) saw unusually-high trading volume on Wednesday after Guggenheim raised their price target on the stock from $40.00 to $55.00. Guggenheim currently has a buy rating on the stock. Approximately 1,793,714 shares traded hands during mid-day trading, an increase of 16% from the previous session’s volume of 1,549,112 shares.The stock last traded at $37.3050 and had previously closed at $35.11.

AMLX has been the topic of several other reports. Wolfe Research upgraded shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday. Robert W. Baird upped their price objective on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday. HC Wainwright raised their target price on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Finally, Citigroup increased their price target on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $36.25.

Insider Activity

In related news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the transaction, the insider owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This trade represents a 7.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.90% of the company’s stock.

Key Stories Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Avexitide achieved the primary endpoint in the Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, reducing hypoglycemic events by 55%. The result strengthens the case for an FDA filing by the end of 2026 and improves the drug’s potential commercial value. AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
• Positive Sentiment: Analysts raised their outlook for Amylyx. HC Wainwright maintained a Buy rating and a $55 price target while increasing its EPS forecasts to $3.22 for 2029 and $6.40 for 2030, reflecting expectations for successful commercialization and substantially higher future revenue. HC Wainwright Raises Amylyx Price Target
• Positive Sentiment: Guggenheim raised its price target to $55 from $40 with a Buy rating, while Robert W. Baird increased its target to $52 from $28 and assigned an Outperform rating. Wolfe Research also upgraded the shares to Strong Buy, adding to the positive analyst momentum.
• Neutral Sentiment: The clinical success has pushed AMLX toward regulatory and commercial execution milestones. Investors will now focus on additional LUCIDITY data, the FDA filing, approval prospects and Amylyx’s ability to establish avexitide commercially.
• Negative Sentiment: Amylyx priced an upsized public offering of 14.09 million shares at $35.50 per share, expected to raise approximately $500 million before expenses. Underwriters may purchase another 2.11 million shares, creating potential dilution and adding supply near the offering price. Amylyx Prices Upsized $500 Million Offering

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at $18,912,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Amylyx Pharmaceuticals by 10.4% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,407 shares of the company’s stock worth $3,114,000 after buying an additional 16,318 shares in the last quarter. Hsbc Holdings PLC boosted its position in Amylyx Pharmaceuticals by 27.5% during the 2nd quarter. Hsbc Holdings PLC now owns 14,554 shares of the company’s stock valued at $269,000 after acquiring an additional 3,140 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at approximately $8,740,845,000. Finally, Almitas Capital LLC purchased a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $17,509,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Performance

The stock has a market cap of $4.33 billion, a P/E ratio of -27.20 and a beta of -0.21. The firm has a 50-day moving average price of $19.38 and a 200-day moving average price of $16.35.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on therapies intended to protect nerve cells and address the underlying biology of conditions such as amyotrophic lateral sclerosis (ALS) and other serious neurological disorders.

Amylyx’s lead product, AMX0035, was marketed in the United States as Relyvrio and in Canada as Albrioza for the treatment of ALS. Following results from a confirmatory clinical trial that did not meet its objectives, the company announced the voluntary withdrawal of the product from the market in 2024.